US Cancer Biotech Stocks Surge 1.7 Trillion Won in a Day: How Long Will the Rebound Last?

ImmunityBio (NASDAQ: IBRX) surged more than 15% on the Nasdaq to close at $6.97 per share. In a single day, its market capitalization jumped by about $1.2 billion (roughly ₩1.7 trillion), lifting its total value to approximately $6.9 billion (around ₩9.3 trillion). Trading volume also exceeded 16.26 million shares, highlighting strengthened short-term momentum.

The company recently reported that net product sales of its bladder cancer immunotherapy ANKTIVA are expected to reach $113 million in 2025—a roughly 700% increase year-over-year. It also secured approvals from the Saudi Food and Drug Authority for non–small cell lung cancer and bladder cancer indications, fueling expectations for global revenue growth. At the same time, ImmunityBio has launched the ResQ215B Phase 2 trial—an outpatient, chemo-free study combining ANKTIVA with its CAR-NK therapy in non-Hodgkin lymphoma—and is in discussions with the U.S. Food and Drug Administration on a resubmission pathway to expand ANKTIVA’s bladder cancer indication.

Nonetheless, regulatory risks remain. The FDA has requested additional data in its review of the bladder cancer label expansion for ANKTIVA, and separate inquiries about the BCG combination regimen have caused temporary share-price volatility.

ImmunityBio is a U.S.-listed biotech firm that develops and commercializes cancer and infectious disease therapies centered on its interleukin-15–based immunotherapy ANKTIVA and CAR-NK cell therapy. ANKTIVA is approved in the U.S. and U.K. as a BCG-combination treatment for non–muscle-invasive bladder cancer. The company is pursuing conditional approvals and label expansions in Europe, Saudi Arabia, and other markets as it aims to become a global immuno-oncology platform company.